As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
25 Analysts have issued a Nurix Therapeutics Inc forecast:
25 Analysts have issued a Nurix Therapeutics Inc forecast:
| Aug '25 |
+/-
%
|
||
| Revenue | 84 84 |
48%
48%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -263 -263 |
47%
47%
|
|
| EBIT (Operating Income) EBIT | -267 -267 |
38%
38%
|
|
| Net Profit | -245 -245 |
38%
38%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
| Head office | United States |
| CEO | Arthur Sands |
| Employees | 286 |
| Founded | 2009 |
| Website | www.nurixtx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


